NCT05202886 is a NA clinical trial of Liver from deceased donors in Brain Death, sponsored by Hospital Vall d'Hebron.

Who is sponsoring NCT05202886?

NCT05202886 is sponsored by Hospital Vall d'Hebron.

What drugs are being tested in NCT05202886?

Interventions in NCT05202886: Liver from deceased donors.

What condition does NCT05202886 study?

NCT05202886 studies Brain Death, Liver Steatosis.

Is NCT05202886 still recruiting?

NCT05202886 is currently status unknown. Last updated 24 January 2022.

Last reviewed 2022-01-24 · How we verify

NCT05202886

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

"LiverColor": Machine Learning in Liver Photographs

Status unknown NA Last updated 24 January 2022

What this trial tests

NA trial testing Liver from deceased donors in Brain Death in 246 participants. Status unknown.

Timeline

30 June 2018

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Hospital Vall d'Hebron
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	246
Start date	30 June 2018
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across Spain

Drugs / interventions tested

Liver from deceased donors

Conditions studied

Brain Death — all drugs for Brain Death →
Liver Steatosis — all drugs for Liver Steatosis →

Sponsor

Hospital Vall d'Hebron

Who can join

Eligibility, any sex, with Brain Death or Liver Steatosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main goal of this project is to create a machine learning model in order to quantify liver steatosis in liver donor faster, more objective and reliable than histological analysis and surgeons point-of-view.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

LiverColor: An Artificial Intelligence Platform for Liver Graft Assessment.
Piella G, Farré N, Esono D, Cordobés MÁ, et al · · 2024 · cited 3× · PMID 39125531 · DOI 10.3390/diagnostics14151654

Verify or expand the search:

Other recruiting trials for Brain Death

Currently open trials in the same condition.

NCT06640088 — Determining ICU Staffs Conceptions, Opinions, Views, Experiences and Reflection of Brain Death and Organ Donation · recruiting

Other Hospital Vall d'Hebron trials

Trials by the same sponsor.

NCT05424809 — Feasibility and Preliminary Effectiveness of a Shared Decision-making Process · NA · unknown
NCT05398380 — Liver Transplantation for Non-resectable Colorectal Liver Metastases: Translational Research · NA · recruiting
NCT04656730 — Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas · Phase 4 · completed
NCT04378023 — Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. · recruiting
NCT06103097 — Histologic Evolution of Patients With Liver Transplantation · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05202886 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Vall d'Hebron
Last refreshed: 24 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05202886.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing